8 AI-Powered Health Startups to Watch in 2026

AI health funding stopped being a broad bet and became a concentrated one. The capital flowing into healthcare AI in 2025 and early 2026 didn't spread evenly across the sector — it piled into a handful of categories where the technology demonstrably works today: ambient clinical documentation, clinical decision support, imaging triage, molecular design, and the unglamorous administrative plumbing that consumes a quarter of every US healthcare dollar. The companies below are where that concentration landed. Every one of them closed a significant round recently, and most did it at valuations that doubled or tripled within a year — the clearest behavioral signal investors can send. If you sell into health tech, invest in it, or compete with it, these are the names to track, and you can watch the next wave arrive in real time on our recently funded companies feed.

Clinical Documentation and Ambient AI Scribes

Ambient documentation is the first AI category to achieve genuine mass adoption inside health systems, because the ROI case is immediate: clinicians spend hours per day on notes, and burnout is the single most expensive workforce problem in medicine. The result is the most aggressively funded segment in health AI.

Abridge

Abridge converts the clinical conversation between doctor and patient into structured, billable documentation in real time. It has become the reference company for the entire ambient AI category: in June 2025 it announced a $300 million Series E led by Andreessen Horowitz at a $5.3 billion valuation — roughly double the valuation it set at its $250 million Series D just four months earlier, per TechCrunch's coverage of the round. Coverage of the raise also pointed to enterprise-scale deployments at Kaiser Permanente and Mayo Clinic, which matters more than the headline number: health systems that standardize on a documentation layer rarely rip it out. Abridge's stated ambition has moved past scribing toward what it calls care intelligence — using the captured conversation as a data asset for coding, orders, and revenue cycle. That expansion is the story to watch in 2026.

Ambience Healthcare

Ambience Healthcare is Abridge's most credible rival, and it competes on a different axis: coding accuracy. Its platform pairs ambient documentation with point-of-care coding and clinical documentation integrity, which speaks directly to CFOs rather than only to burned-out physicians. The company announced a $243 million Series C in July 2025, co-led by Oak HC/FT and Andreessen Horowitz with participation from the OpenAI Startup Fund, at a valuation Modern Healthcare reported as $1.25 billion. Per the company's announcement, it serves more than 100 health system entities including Cleveland Clinic, UCSF Health, Houston Methodist, and Memorial Hermann. In a category where the top two players raised over half a billion dollars in a single summer, the second-place position is still an enormous business.

Clinical Knowledge and Decision Support

The fastest-growing consumer-style product in medicine isn't for consumers at all — it's for the clinicians making decisions at the point of care.

OpenEvidence

OpenEvidence is an AI-powered medical search and clinical reference tool, free to verified US clinicians and monetized in part through advertising — a model closer to Google's than to a typical health IT vendor's. Its funding trajectory over twelve months is one of the steepest in the sector's history: a $210 million round at a $3.5 billion valuation in July 2025, then a $250 million Series D co-led by Thrive Capital and DST Global in January 2026 that doubled the valuation to $12 billion, per the company's announcement and CNBC's reporting. The same announcement claimed roughly 18 million clinical consultations supported in December 2025 alone. Whatever you think of the valuation, the usage is the point: OpenEvidence is becoming the default second opinion for a meaningful share of practicing US physicians, and distribution like that is nearly impossible to dislodge.

Diagnostics, Imaging, and Devices

Imaging was the first clinical domain where AI cleared regulatory bars at scale, and the leaders have now moved from single-purpose algorithms to platform plays.

Aidoc

Aidoc started with AI triage for radiology — flagging suspected strokes, hemorrhages, and embolisms in CT scans so critical cases jump the queue — and has compounded that into one of the deepest regulatory moats in health AI, with 17 FDA-cleared algorithms per the company. Its CARE clinical foundation model received FDA clearance as a CT-based triage solution across 11 indications, a signal that regulators are beginning to accommodate foundation-model approaches rather than only narrow single-task tools. In 2026 Aidoc announced a $150 million Series E led by the growth equity business at Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank, and NVIDIA's NVentures, bringing total funding above $500 million per the announcement. The company says its technology is deployed across roughly 2,000 hospitals and analyzes more than 60 million patient cases a year.

Eko Health

Eko Health put AI inside the most ubiquitous instrument in medicine: the stethoscope. Its FDA-cleared algorithms detect structural heart murmurs and low ejection fraction — an early-warning signal for heart failure — during a routine physical exam, on hardware a clinician already holds. The company announced a $41 million Series D with investors including ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital, bringing total funding above $165 million per its announcement, and says its platform is used by more than 500,000 clinicians. Eko matters in 2026 because it represents the opposite thesis from the imaging giants: instead of AI in the radiology suite, it pushes screening-grade AI to the front line of primary care, where heart disease is actually first missed.

Drug Discovery and Molecular Design

AI drug discovery has survived its hype cycle and its backlash, and the companies still raising mega-rounds are the ones with credible scientific pedigrees and platform economics rather than single-asset stories.

Isomorphic Labs

Isomorphic Labs is Alphabet's AI drug design company, built on the same research lineage as DeepMind's AlphaFold. In March 2025 it announced a $600 million external investment round — its first — led by Thrive Capital with participation from GV and follow-on capital from Alphabet, per the company's announcement. The stated purpose is telling: advancing its next-generation AI drug design engine and pushing its own therapeutic programs toward the clinic, alongside existing partnerships with major pharmaceutical companies. Isomorphic is the bellwether for the entire category. If a structure-prediction-native company can move a wholly AI-designed program into clinical trials on a compressed timeline, the economics of pharma R&D change; 2026 is the window when that claim starts getting tested.

Chai Discovery

Chai Discovery is the fastest-moving newcomer in molecular design. Founded in 2024, the San Francisco lab builds foundation models that predict and reprogram interactions between biomolecules, with a particular focus on antibody design. Its 2025 was extraordinary by biotech standards: a $70 million Series A announced in August, then a $130 million Series B led by Oak HC/FT and General Catalyst in December at a $1.3 billion valuation, with OpenAI and Thrive Capital among the investors and total funding above $225 million, per the company's announcements. Chai is worth watching as the purest test of whether frontier-lab AI talent — its team draws from OpenAI and Stripe backgrounds — can out-execute incumbent computational biology companies with a fraction of the headcount.

Mental Health

Mental health AI split into two distinct bets in 2025: consumer-facing AI that delivers support directly, and AI-powered infrastructure that makes human clinicians more precise. Both are represented below, and we cover the broader field in our roundup of the top mental health startups of 2026.

Slingshot AI

Slingshot AI launched Ash in July 2025, positioning it as the first AI built specifically for therapy — a purpose-built foundation model for psychology rather than a general chatbot with a therapy prompt. At launch the company had raised $93 million, with the most recent capital led by Radical Ventures and Forerunner Ventures alongside earlier backers including Andreessen Horowitz, per Forbes and STAT coverage, and said Ash had been developed with around 50,000 beta users. Slingshot is the company to watch on the hardest question in digital mental health: whether a consumer AI product can deliver measurable clinical benefit while regulators, clinicians, and app stores are all scrutinizing AI therapy claims more closely than ever. If Ash clears that bar, the category reopens; if it stumbles, expect the funding window for consumer therapy AI to narrow fast.

Spring Health

Spring Health takes the opposite approach: AI as the routing layer, humans as the treatment. Its precision mental healthcare platform uses machine learning to match employees to the right modality — therapy, coaching, medication management — on the first attempt instead of the third. The company announced a $100 million Series E led by Generation Investment Management in July 2024 at a $3.3 billion valuation, and said at the time that it covered more than 10 million lives through over 400 employers plus payer and channel relationships. In a 2026 environment where employers are auditing every benefits line item, Spring's outcome-based positioning — optimizing for clinical fit rather than engagement — is the durable version of the mental health benefits story.

Care Navigation and Admin Automation

The least glamorous category on this list may be the most fundable. Administrative overhead is the one part of healthcare where full automation is both technically feasible and universally wanted — nobody defends the fax machine.

Tennr

Tennr automates the referral workflows that still run on faxes and unstructured documents — the exact place patients get lost between providers. Its language models read incoming referrals, extract and verify the clinical and insurance information, and route the patient forward without a human retyping anything. The company announced a $101 million Series C led by IVP in June 2025, with participation from Andreessen Horowitz, Lightspeed, GV, ICONIQ, and Foundation Capital, at a valuation Fortune reported as $605 million. Referrals are a wedge, not the endgame: each automated document teaches the system more of the payer-provider back office, which is why investors priced a document-processing company like an infrastructure play.

SmarterDx

SmarterDx applies clinical AI to a problem hospital CFOs can quantify to the dollar: revenue leakage from incomplete documentation and coding. Its system re-reviews every patient chart before the bill goes out, catching diagnoses that were treated but never captured. The company raised a $50 million Series B led by Transformation Capital, bringing total funding to $71 million per its announcement, which also cited an average of $2 million in net new annual revenue per 10,000 discharges for its hospital clients. SmarterDx is on this list because it represents the most repeatable go-to-market in health AI right now: a tool that pays for itself out of found money, sold into a buyer who can verify the claim within a quarter.

Qventus

Qventus automates hospital operations — surgical scheduling, discharge planning, patient flow — the logistics layer that determines whether a health system's most expensive assets sit idle. In January 2025 it announced a $105 million Series D led by KKR, with participation from Bessemer Venture Partners and strategic investment from health systems including Northwestern Medicine, HonorHealth, and Allina Health, per the company's announcement. That investor list is the tell: when your customers put capital into your round, the product has moved from pilot to dependency. Qventus says its platform is used across more than 115 hospitals, and its "AI operational assistants" push the company from analytics into direct workflow automation — the transition every hospital-operations vendor must make in 2026 or lose relevance.

Patient-Facing Clinical Agents

The most contentious frontier in health AI is letting the model talk to the patient directly. One company has raised more than anyone else on the thesis that this can be done safely for non-diagnostic work.

Hippocratic AI

Hippocratic AI builds generative AI agents that handle patient-facing, non-diagnostic clinical work over the phone — pre-operative instructions, chronic care check-ins, medication reminders, post-discharge follow-up — the calls health systems chronically understaff. The company announced a $126 million Series C led by Avenir Growth in November 2025 at a $3.5 billion valuation, following a $141 million Series B led by Kleiner Perkins in January 2025, with health systems including Universal Health Services, WellSpan Health, and Cincinnati Children's participating in the latest round per the announcement. Hippocratic's obsessive safety positioning — constraining agents to tasks below the diagnostic line — is both its regulatory shield and its market wedge. If staffing shortages persist through 2026, and every workforce projection says they will, demand for this category is structural.

What These Companies Signal for 2026

Read across the list and a few patterns hold up:

• The money follows deployment, not demos. Nearly every round above cites named health systems in production, not pilots. Investor diligence in this sector now starts with "who has rolled this out enterprise-wide."
• Foundation models are becoming regulated medical products. Aidoc's cleared CT triage model and the ambient scribes' coding integrations show the FDA and the compliance stack adapting to general-purpose models rather than blocking them.
• Admin automation is the quiet compounder. Tennr, SmarterDx, and Qventus sell into budget lines that already exist, which is why their categories keep producing new funded entrants every month.
• Strategic capital is in the round. Health systems, Alphabet, OpenAI's fund, NVIDIA, and Goldman Sachs all appear above — a sign that the buyers and platforms are underwriting the sector's winners directly.

Healthcare AI is also not one market. The investors behind an ambient scribe rarely overlap with the ones behind an antibody-design lab, which is why segmenting by precise vertical matters more here than almost anywhere else — our industry directories break funded companies out at that level of granularity.

Methodology note: companies were selected based on publicly announced funding rounds and category momentum through mid-2026, with funding details drawn from company announcements and reporting by outlets including TechCrunch, STAT, Fierce Healthcare, CNBC, Fortune, and Modern Healthcare. This is a representative watchlist, not an exhaustive ranking, and inclusion is not investment advice.

If you sell to, recruit from, or invest in this market, the companies above are just the visible tip — hundreds of AI health startups raise new rounds every quarter. VCBacked tracks every funded AI health startup with verified funding data and founder contact information, searchable by industry, stage, and location, updated daily.